Skip to main content
. 2023 Jun 12;83(16):2675–2689. doi: 10.1158/0008-5472.CAN-22-3645

Figure 4.

Figure 4. Syk inhibition reduces tumor growth and sensitizes PDAC tumors to gemcitabine. A, Schemas for the administration of R788 or anti-PDL1 mAb or Gem in Panc02 or KPC1245 tumors. B and C, Weights of pancreata from Panc02 (B) and KPC1245 (C) tumors treated with drugs (n = 5) as depicted in schema in A. D, Metastatic nodules in treated KPC1245 (n = 5) PDAC tumors. Significance testing was performed by one-way ANOVA with Tukey post hoc multiple pairwise testing. E, Weights of pancreata from KPC1242 tumors treated with drugs (n = 5) as depicted in schema. F, Images showing Trichrome staining in PDAC tumors. Scale bar, 50 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

Syk inhibition reduces tumor growth and sensitizes PDAC tumors to gemcitabine. A, Schemas for the administration of R788 or anti-PDL1 mAb or Gem in Panc02 or KPC1245 tumors. B and C, Weights of pancreata from Panc02 (B) and KPC1245 (C) tumors treated with drugs (n = 5) as depicted in schema in A. D, Metastatic nodules in treated KPC1245 (n = 5) PDAC tumors. Significance testing was performed by one-way ANOVA with Tukey post hoc multiple pairwise testing. E, Weights of pancreata from KPC1242 tumors treated with drugs (n = 5) as depicted in schema. F, Images showing Trichrome staining in PDAC tumors. Scale bar, 50 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.